Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.

Blood - 7 Nov 2013

Vainstein Vladimir, Eide Christopher A, O'Hare Thomas, Shukron Ofir, Druker Brian J

Abstract excerpt

BCR-ABL mutations result in clinical resistance to ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Although in vitro 50% inhibitory concentration (IC(50)) values for specific mutations have been suggested to guide TKI choice in the clinic, the quantitative relationship be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Biomarkers, Pharmacological
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Inhibitory Concentration 50

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 24062017
DOI: 10.1182/blood-2012-08-452409
PMCID: PMC3821725

Genes

BCR
IPP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24062017-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.PMID 24062017Read ↗

Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.Semantic proximity Read ↗

Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?Semantic proximity Read ↗

Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.Semantic proximity Read ↗

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.Semantic proximity Read ↗

Beyond IC <sub>50</sub> - A computational dynamic model of drug resistance in enzyme inhibition treatmentSemantic proximity Read ↗

Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.Semantic proximity Read ↗

A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.Semantic proximity Read ↗

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.Semantic proximity Read ↗

Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodiesSemantic proximity Read ↗

Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.Semantic proximity Read ↗

Quantitatively Correlating interactions between three intrinsic kinetic processes to in vivo protein kinase occupancySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.